Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?

Autoimmunity Reviews

Volumn 13, Issue 12, 2014, Pages 1167-1173

  Alunno, Alessia ^a   Carubbi, Francesco ^b   Bartoloni, Elena ^a   Bistoni, Onelia ^a   Caterbi, Sara ^a   Cipriani, Paola ^b   Giacomelli, Roberto ^b   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BELIMUMAB; BRODALUMAB; DEXAMETHASONE; FORKHEAD TRANSCRIPTION FACTOR; GUSELKUMAB; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 6; IXEKIZUMAB; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; USTEKINUMAB;

APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DENDRITIC CELL; DISEASE DURATION; DRUG TARGETING; HUMAN; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENICITY; PLASTICITY; REVIEW; SJOEGREN SYNDROME; TH17 CELL; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; IMMUNOLOGY; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TH17 CELLS;

EID: 84908874664     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.022     Document Type: Review

References (97)

1. Mavragani C.P., Nezos A., Moutsopoulos H.M. New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 2013, 25:623-629.
2. Nocturne G., Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013, 9:544-556.
3. Giannouli S. Predicting progression to lymphoma in Sjogren's syndrome patients. Expert Rev Clin Immunol 2014, 10:501-512.
4. Ziakas P.D., Poulou L.S., Thanos L. Towards integrating positron emission tomography for work-up of patients with Sjögren's syndrome and associated lymphomas. Autoimmun Rev 2014 Mar, 13(3):327-329.
5. Burbelo P.D., Ambatipudi K., Alevizos I. Genome-wide association studies in Sjögren's syndrome: what do the genes tell us about disease pathogenesis?. Autoimmun Rev 2014, 13(7):756-761.
6. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev 2013, 12(11):1046-1051.
7. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010, 34(4):400-407.
8. Kapsogeorgou E.K., Christodoulou M.I., Panagiotakos D.B., Paikos S., Tassidou A., Tzioufas A.G., et al. Minor salivary gland inflammatory lesions in Sjögren syndrome: do they evolve?. J Rheumatol 2013, 40(9):1566-1571.
9. Zhou D., Chen Y.T., Chen F., Gallup M., Vijmasi T., Bahrami A.F., et al. Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye. Am J Pathol 2012, 181(3):753-760.
10. Gizinski A.M. Fox DA T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol 2014, 26:204-210.
11. Rouvier E., Luciani M.F., Mattéi M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150:5545-5456.
12. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
13. Gu C., Wu L., Li X. IL-17 family: cytokines, receptors and signaling. Cytokine 2013, 64:477-485.
14. van den Berg W.B., McInnes I.B. Th17 cells and IL-17 a focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013, 43:158-170.
15. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3(6):811-821.
16. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 2008, 43:402-407.
17. Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36-39.
18. Maitra A., et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction. Proc Natl Acad Sci U S A 2007, 104(18):7506-7511.
19. Liu S., Song X., Chrunyk B.A., Shanker S., Hoth L.R., Marr E.S., et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013, 4:1888.
20. Qian Y., Liu C., Hartupee J., Altuntas C.Z., Gulen M.F., Jane-Wit D., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8:247-256.
21. Muhl H., Bachmann M., Pfeilschifter J. Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity. Cell Microbiol 2011, 13:340-348.
22. Sugihara T., Kobori A., Imaeda H., Tsujikawa T., Amagase K., Takeuchi K., et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010, 160:386-393.
23. Lee J.H., Cho M.L., Kim J.I., Moon Y.M., Oh H.J., Kim G.T., et al. Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol 2009, 36:684-692.
24. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476. [9].
25. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
26. Korn T., Oukka M., Kuchroo V., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007, 19:362-371.
27. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
28. Aggarwal S., Ghilardi N., Xie M., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
29. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 10.1016/j.autrev.2013.12.004.
30. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
31. Liu S.M., King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013, 191:3501-3506.
32. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
33. Korn T., Bettelli E., Gao W., Awasthi A., Jarger A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007, 448:484-487.
34. Craft J.E. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 2012, 8:337-347.
35. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10(8):857-863.
36. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203(10):2271-2279.
37. Yang X., Zheng S.G. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev 2014, 13:615-620.
38. Crispín J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181:8761-8766.
39. Alunno A., Bistoni O., Bartoloni E., Caterbi S., Bigerna B., Tabarrini A., et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013, 72:286-292.
40. Juvet S.C., Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol 2012, 4(1):48-58.
41. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21:274-280.
42. Komatsu N., Okamoto K., Sawa S., Nakashima T., Oh-Hora M., Kodama T., et al. Pathogenic conversion of Foxp3(+) T cells into TH17 cells in autoimmune arthritis. Nat Med 2014 Jan, 20(1):62-68.
43. Sharma M.D., Hou D.Y., Liu Y., Koni P.A., Metz R., Chandler P., et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009, 113:6102-6111.
44. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010, 9(11):785-792.
45. Benedetti G., Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 2014, 44:339-347.
46. Chen D.Y., Chen Y.M., Wen M.C., Hsieh T.Y., Hung W.T., Lan J.L. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012, 21(13):1385-1396.
47. Shao S., He F., Yang Y., Yuan G., Zhang M., Yu X. Th17 cells in type 1 diabetes. Cell Immunol Nov 2012, 280(1):16-21.
48. Boggio E., Clemente N., Mondino A., Cappellano G., Orilieri E., Gigliotti C.L., et al. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood 2014, 123:1178-1186.
49. Dong W., Zhu P. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics. Autoimmun Rev 2012, 11(12):844-851.
50. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome. Arthritis Rheum 2008, 58:734-774.
51. Nguyen C.Q., Yin H., Lee B.H., Carcamo W.C., Chiorini J.A., Peck A.B. Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2010, 12:R220.
52. Lin X., Rui K., Deng J., Tian J., Wang X., Wang S., et al. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204584.2014.
53. Fei Y., Zhang W., Lin D., Wu C., Li M., Zhao Y. Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren's syndrome. Clin Rheumatol 2014, 33:523-529.
54. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
55. Kang K.Y., Kim H.-O., Kwok S.-K., Ju J.H., Park K.-S., Sun D.-I., et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011, 13:R179.
56. Ciccia F., Guggino G., Rizzo A., Ferrante A., Raimondo S., Giardina A., et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012, 71(2):295-301.
57. Ciccia F., Guggino G., Rizzo A., Alessandro R., Carubbi F. GiardinaRituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2014, 53:1313-1322.
58. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 2010, 6:529-537.
59. Alunno A., Carubbi F., Caterbi S., Bistoni O., Bartoloni E., Giacomelli R., et al. The role of T helper 17 cell subsets in Sjogren's syndrome: similarities and differences between mouse model and humans. Ann Rheum Dis 2014, 73(7):e42.
60. Apostolidis S.A., Crispín J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus Feb 2011, 20(2):120-124.
61. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008, 181:2898-2906.
62. Alunno A., Carubbi F., Bistoni O., Caterbi S., Bartoloni E., Bigerna B., et al. CD4-CD8- T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. J Autoimmun 2014, 51:38-43.
63. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:1299-1304.
64. Gullick N.J., Abozaid H.S., Jayaraj D.M., Evans H.G., Scott D.L., Choy E.H., et al. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol 2013, 174(2):292-301.
65. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
66. Mieliauskaite D., Dumalakiene I., Rugiene R., Mackiewicz Z. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome. Clin Dev Immunol 2012, 10.1155/2012/187258.
67. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011, 70(8):1363-1368.
68. Carubbi F., Alunno A., Cipriani P., Di Benedetto P., Ruscitti P., Berardicurti O., et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological and molecular features: a retrospective study. Semin Arthritis Rheum 2014, 10.1016/j.semarthrit.2014.05.015.
69. Manzo A., Bombardieri M., Humby F., Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010, 233:267-285.
70. Astorri E., Bombardieri M., Gabba S., Peakman M., Pozzilli P., Pitzalis C. Evolution of ectopic lymphoid neogenesis and in situ autoantibody production in autoimmune nonobese diabetic mice: cellular and molecular characterization of tertiary lymphoid structures in pancreatic islets. J Immunol 2010, 185(6):3359-3368.
71. Risselada A.P., Looije M.F., Kruize A.A., Bijlsma J.W., van Roon J.A. The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review. Semin Arthritis Rheum 2013 Feb, 42(4):368-376.
72. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.
73. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
74. Seror R., Gottenberg J.E., Devauchelle-Pensec V., Dubost J.J., Le Guern V., Hayem G., et al. ESSDAI and ESSPRI: EULAR indexes for a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res 2013, 65:1358-1364.
75. De Paiva C.S., Chotikavanich S., Pangelinan S.B. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009, 2(3):243-253.
76. Lee S.Y., Han S.J., Nam S.M., Yoon S.C., Ahn J.M., Kim T.I., et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol 2013, 156:247-253.
77. Tan X., Sun S., Liu Y., Zhu T., Wang K., Ren T., et al. Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye (Lond) 2014, 28:608-613.
78. Ramos-Casals M., Brito-Zerón P., Sisó-Almirall A., Bosch X., Tzioufas A.G. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012, 8(7):399-411.
79. Ramos-Casals M., Tzioufas A.G., Stone J.H., Sisó A., Bosch X. Treatment of primary Sjögren syndrome. A systematic review. JAMA 2010, 304(4):452-460.
80. Carubbi F., Cipriani P., Marrelli A., Benedetto P., Ruscitti P., Berardicurti O., et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013, 15(5):R172.
81. Mariette X., Seror R., Quartuccio L., Baron G., Salvin S., Fabris M., et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013-203991.
82. Abdulahad W.H., Meijer J.M., Kroese F.G., Meiners P.M., Vissink A., Spijkervet F.K., et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011, 63(4):1116-1123.
83. van de Veerdonk F.L., Lauwerys B., Marijnissen R.J., Timmermans K., Di Padova F., Koenders M.I., et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011, 63(6):1507-1516.
84. Ciccia F., Giardina A., Rizzo A., Guggino G., Cipriani P., Carubbi F., et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013, 72(5):782-783.
85. Roescher N., Tak P.P., Illei G.G. Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010, 69(6):945-948.
86. Adler S., Körner M., Förger F., Huscher D., Caversaccio M.D., Villiger P.M. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome. a pilot study Arthritis Care Res 2013, 65:1862-1868.
87. Meiners P.M., Vissink A., Kroese F.G., Spijkervet F.K., Smitt-Kamminga N.S., Abdulahad W.H., et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014, 73:1393-1396.
88. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012 Oct, 11(10):763-776.
89. Williams S.C. Flurry of deal-making surrounds new autoimmunity target. Nat Med 2013, 19(9):1078.
90. Vugmeyster Y., Zhang Y.E., Zhong X., Wright J., Leung S.S. Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice. Int Immunopharmacol 2014, 18(2):225-227.
91. Tse M.T. IL-17 antibodies gain momentum. Nat Rev Drug Discov 2013, 12:815-816.
92. Buckland J. Therapy: ustekinumab therapeutic effects-more than skin deep. Nat Rev Rheumatol 2013, 9:445.
93. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014, 73:990-999.
94. Sofen H., Smith S., Matheson R.T., Leonardi C.L., Calderon C., Brodmerkel C., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014, 133(4):1032-1040.
95. Hua F., Comer G.M., Stockert L., Jin B., Nowak J., Pleasic-Williams S., et al. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014, 54(1):14-22.
96. Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014, 211:89-104.
97. Solt L.A., Kumar N., Nuhant P., Wang Y., Lauer J.L., Liu J., et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472:491-494.